Drug Profile

Research programme: potassium channel agonists - Bausch Health Companies

Alternative Names: VRX 698

Latest Information Update: 18 Jul 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Valeant Pharmaceuticals International
Developer Bausch Health Companies
Class Carbamates; Phenylenediamines; Small molecules
Mechanism of Action KCNQ potassium channel agonists; Potassium channel agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
29 Feb 2012 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
29 Feb 2012 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com